PTGX — PROTAGONIST THERAPEUTICS INC

Ownership history in SUPERSTRING CAPITAL MANAGEMENT LP  ·  3 quarters on record

This page tracks every 13F SEC filing in which SUPERSTRING CAPITAL MANAGEMENT LP reported a position in PROTAGONIST THERAPEUTICS INC (PTGX). Data includes quarterly share count, position size as % of portfolio, estimated market value, and end-of-quarter stock price — sourced directly from SEC EDGAR 13F filings.

Peak position
6.21% (2023 Q4)
Avg. % of fund
3.28%
First filed
2023 Q4
Last filed
2025 Q3
Quarters held
3
Quarter Action Shares Change Chg % % of Fund Mkt Value Price (EOQ)
2025 Q3 REDUCED 20,358 -48,534 -70.4% 1.33% $1.4M $66.43
2024 Q4 REDUCED 68,892 -310,251 -81.8% 2.30% $2.7M $38.60
2023 Q4 INITIATED 379,143 — — 6.21% $8.7M —
% of Fund (quarterly)    PTGX price (monthly, adj. close)

Other funds also holding PTGX

As of 2025 Q4 — sorted by position size

JOHNSON & JOHNSON 3Y 38.57% AIHC Capital Management Ltd 15.54% ADAR1 Capital Management, LLC 6.63% Nationale-Nederlanden Powszechne Towarzystwo Emerytalne S.A. 4.43% RTW INVESTMENTS, LP 3Y 7Y 4.43% Knott David M Jr 3Y 2.95% Birchview Capital, LP 3Y 7Y 2.81% Commodore Capital LP 3Y 2.62% FARALLON CAPITAL MANAGEMENT LLC 3Y 7Y 2.53% PERCEPTIVE ADVISORS LLC 3Y 7Y 2.1%
← Back to SUPERSTRING CAPITAL MANAGEMENT LP Holdings